Clinical Trial: A Phase 2 Study of PTX 100 in Patients with Relapsed/refractory CTCL

U.S., March 4 -- ClinicalTrials.gov registry received information related to the study (NCT06854653) titled 'A Phase 2 Study of PTX 100 in Patients with Relapsed/refractory CTCL' on Feb. 18.

Brief Summary: This is an open-label, phase 2 randomized study to evaluate the efficacy, safety, pharmacokinetics (PK) and pharmadynamics (PD), of PTX-100 monotherapy at 500 or 1000 mg/m2 in patients with relapsed/refractory Cutaneous T-Cell Lymphoma (CTCL).

PTX-100 will be administered by IV infusion over 60 minutes on days 1 to 5 of a 14-day cycle for 4 cycles, then 21 day cycle thereafter. Subjects will be treated or followed up, if subjects discontinue treatment, for up to 18 months.

Study Start Date: March 01

Study Type: INTERVENTIONAL

Conditi...